Dutta R, Trapp BD (2011) Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol 93:1–12
Article
PubMed
Google Scholar
Hagemeier K, Bruck W, Kuhlmann T (2012) Multiple sclerosis—remyelination failure as a cause of disease progression. Histol Histopathol 27:277–287
CAS
PubMed
Google Scholar
Kuhlmann T, Miron V, Cui Q, Wegner C, Antel J, Bruck W (2008) Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131:1749–1758
CAS
Article
PubMed
Google Scholar
Wang R, Chen Y, Guo T, Zhen W, Guo T, Zhao R, Liu AA, Rubio JP, Krull D, Lu J, Song M, Thompson P (2014) Histamine H3 receptor negatively regulates oligodendrocyte differentiation and myelination. Mult Scler 20(S1):341
Google Scholar
Mei F, Fancy SP, Shen YA, Niu J, Zhao C, Presley B, Miao E, Lee S, Mayoral SR, Redmond SA, Etxeberria A, Xiao L, Franklin RJ, Green A, Hauser SL, Chan JR (2014) Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med 20:954–960
CAS
Article
PubMed
PubMed Central
Google Scholar
Grove RA, Harrington CM, Mahler A, Beresford I, Maruff P, Lowy MT, Nicholls AP, Boardley RL, Berges AC, Nathan PJ, Horrigan JP (2014) A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease. Curr Alzheimer Res 11:47–58
CAS
Article
PubMed
Google Scholar
Nathan PJ, Boardley R, Scott N, Berges A, Maruff P, Sivananthan T, Upton N, Lowy MT, Nestor PJ, Lai R (2013) The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H3 receptor antagonist in patients with mild to moderate Alzheimer’s disease: a preliminary investigation. Curr Alzheimer Res 10:240–251
CAS
Article
PubMed
Google Scholar
Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, Lieberman JA, Marder SR, Maruff P, McMahon RP, Seidman LJ, Peykamian MA (2015) A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophr Res 164:136–142
Article
PubMed
Google Scholar
Ashworth S, Berges A, Rabiner EA, Wilson AA, Comley RA, Lai RY, Boardley R, Searle G, Gunn RN, Laruelle M, Cunningham VJ (2014) Unexpectedly high affinity of a novel histamine H3 receptor antagonist, GSK239512, in vivo in human brain, determined using PET. Br J Pharmacol 171:1241–1249
CAS
Article
PubMed
PubMed Central
Google Scholar
Dousset V, Grossman RI, Ramer KN, Schnall MD, Young LH, Gonzalez-Scarano F, Lavi E, Cohen JA (1992) Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology 182:483–491
CAS
Article
PubMed
Google Scholar
Turati L, Moscatelli M, Mastropietro A, Dowell NG, Zucca I, Erbetta A, Cordiglieri C, Brenna G, Bianchi B, Mantegazza R, Cercignani M, Baggi F, Minati L (2015) In vivo quantitative magnetization transfer imaging correlates with histology during de- and remyelination in cuprizone-treated mice. NMR Biomed 28:327–337
CAS
Article
PubMed
Google Scholar
Merkler D, Boretius S, Stadelmann C, Ernsting T, Michaelis T, Frahm J, Brück W (2005) Multicontrast MRI of remyelination in the central nervous system. NMR Biomed 18:395–403
Article
PubMed
Google Scholar
Deloire-Grassin MS, Brochet B, Quesson B, Delalande C, Dousset V, Canioni P, Petry KG (2000) In vivo evaluation of remyelination in rat brain by magnetization transfer imaging. J Neurol Sci 178:10–16
CAS
Article
PubMed
Google Scholar
Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH (2004) Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 56:407–415
Article
PubMed
Google Scholar
Schmierer K, Wheeler-Kingshott CA, Tozer DJ, Boulby PA, Parkes HG, Yousry TA, Scaravilli F, Barker GJ, Tofts PS, Miller DH (2008) Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation. Magn Reson Med 59:268–277
Article
PubMed
PubMed Central
Google Scholar
Barkhof F, Bruck W, De Groot CJ, Bergers E, Hulshof S, Geurts J, Polman CH, van der Valk P (2003) Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 60:1073–1081
Article
PubMed
Google Scholar
Chen JT, Collins DL, Freedman MS, Atkins HL, Arnold DL (2005) Local magnetization transfer ratio signal inhomogeneity is related to subsequent change in MTR in lesions and normal-appearing white-matter of multiple sclerosis patients. Neuroimage 25:1272–1278
CAS
Article
PubMed
Google Scholar
World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191–2194
Article
Google Scholar
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302
Article
PubMed
PubMed Central
Google Scholar
Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911
CAS
Article
PubMed
Google Scholar
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O’Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83:278–286
Article
PubMed
PubMed Central
Google Scholar
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452
CAS
Article
PubMed
Google Scholar
van den Elskamp IJ, Knol DL, Vrenken H, Karas G, Meijerman A, Filippi M, Kappos L, Fazekas F, Wagner K, Pohl C, Sandbrink R, Polman CH, Uitdehaag BM, Barkhof F (2010) Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. Mult Scler 16:660–669
Article
PubMed
Google Scholar
Brown RA, Narayanan S, Arnold DL (2013) Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis. Neuroimage 66:103–109
Article
PubMed
Google Scholar
Brown RA, Narayanan S, Stikov N, Cook S, Cadavid D, Wolansky L, Arnold DL (2016) MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. Neurology 97:905–911
Article
Google Scholar
Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW (1995) A health-related quality of life measure for multiple sclerosis. Qual Life Res 4:187–206
CAS
Article
PubMed
Google Scholar
Brown RA, Narayanan S, Arnold DL (2014) Imaging of repeated episodes of demyelination and remyelination in multiple sclerosis. Neuroimage Clin 6:20–25
Article
PubMed
PubMed Central
Google Scholar
Goodman SN (1999) Toward evidence-based medical statistics. 2: the Bayes factor. Ann Intern Med 130:1005–1013
CAS
Article
PubMed
Google Scholar
Berry DA (2006) Bayesian clinical trials. Nat Rev Drug Discov 5:27–36
CAS
Article
PubMed
Google Scholar
Brown RA, Narayanan S, Atkins HL, Marder SR, Arnold DL (2011) Normalization of magnetization transfer ratio MRI for multicentre clinical trials. Proc Int Soc Magn Reson Med 19:4082
Google Scholar
Guttmann CR, Ahn SS, Hsu L, Kikinis R, Jolesz FA (1995) The evolution of multiple sclerosis lesions on serial MR. AJNR Am J Neuroadiol 16:1481–1491
CAS
Google Scholar
Gaitan MI, Shea CD, Evangelou IE, Stone RD, Fenton KM, Bielekova B, Massacesi L, Reich DS (2011) Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol 70:22–29
CAS
Article
PubMed
PubMed Central
Google Scholar
Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, Miller D, Guttmann CR, Weiner HL, Gasperini C, Filippi M (1999) Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 353:964–969
CAS
Article
PubMed
Google Scholar
Niklas A, Sebraoui H, Hess E, Wagner A, Then Bergh F (2009) Outcome measures for trials of remyelinating agents in multiple sclerosis: retrospective longitudinal analysis of visual evoked potential latency. Mult Scler 15:68–74
CAS
Article
PubMed
Google Scholar
Thomae E, Niklas A, Sebraoui H, Baum P, Wagner A, Then Bergh F (2010) Improving test–retest variability of visual-evoked responses in multiple sclerosis: implications for trial design. J Clin Neurophysiol 27:270–273
Article
PubMed
Google Scholar